Skip to content

Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients

Enrolling by invitationNCT06808321
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Evaluation of the clinical outcomes of Benidipine initiated by physician's preference in patients with hypertension and/or angina pectoris (chronic coronary syndrome) presenting to cardiology outpatient clinics in Turkey.

Study details

Official title
Evaluation of Clinical Outcomes of Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients in the Turkish Population
Conditions
Interventions
  • Drug: Benidipine Hydrochloride
Sponsor
The Society of Prevention and Awareness of Cardiovascular Diseases
Start date
2025-03-01
Primary completion
2026-01-01
Sex
All
Age range
from 18 Years to 80 Years
Results posted
No results posted in this snapshot
Countries
Turkey (Türkiye)
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with hypertension and/or angina pectoris on the background of chronic coronary syndrome who have been receiving Benidipine treatment for at least 1 month and will continue to receive Benidipine treatment * Male or female outpatients, 18-80 years of age * Patients with mild to moderate essential hypertension who have been receiving or will continue Benidipine treatment for at least 1 month * Outpatients with clinically stable angina pectoris and patients who have been receiving or will continue Benidipine treatment for at least 1 month * Those who signed the written informed consent form Exclusion Criteria: * Patients with secondary hypertension * Emergency hypertensive patients * Having to take other medications during the study that may affect blood pressure * Allergic to DHP calcium antagonists * Evidence of decompensated congestive heart failure, unstable angina or severe arrhythmia * Severe renal or hepatic dysfunction * Pregnant or lactating women * Participation in other clinical trials within 3 months prior to this study * Patients who did not sign the consent form of the study

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06808321